Screener
ImmunityBio, Inc. IBRX Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
$404.3Mlong term debt+$53.0Kcurrent portion long term debt+$213.0Kfinance lease liabilities=$445.39M
Plus components not separately reported this period.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s total debt?
- ImmunityBio, Inc. (IBRX) reported total debt of $445.39M in Q1 2026.
- How has ImmunityBio, Inc.'s total debt changed year-over-year?
- ImmunityBio, Inc.'s total debt increased by 32.2% year-over-year, from $336.84M to $445.39M.
- What is the long-term trend for ImmunityBio, Inc.'s total debt?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total debt has grown at a 88.7% compound annual growth rate (CAGR), from $15.31M to $365.93M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.
Ask your AI about ImmunityBio, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude